Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum. by Xiao, Xia et al.
UCLA
UCLA Previously Published Works
Title
Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal 
Infection Model of Mycoplasma gallisepticum.
Permalink
https://escholarship.org/uc/item/1js6h0xn
Authors
Xiao, Xia
Sun, Jian
Yang, Tao
et al.
Publication Date
2016
DOI
10.3389/fvets.2016.00075
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
September 2016 | Volume 3 | Article 751
Original research
published: 06 September 2016
doi: 10.3389/fvets.2016.00075
Frontiers in Veterinary Science | www.frontiersin.org
Edited by: 
Zong-Hui Yuan, 
Huazhong Agricultural University, 
China
Reviewed by: 
Ayhan Filazi, 
Ankara University, Turkey  
Begum Yurdakok Dikmen, 
Ankara University, Turkey
*Correspondence:
Ya-Hong Liu  
gale@scau.edu.cn
†Xia Xiao and Jian Sun contributed 
equally to this work.
Specialty section: 
This article was submitted to 
Veterinary Pharmacology 
and Toxicology, 
a section of the journal 
Frontiers in Veterinary Science
Received: 20 July 2016
Accepted: 23 August 2016
Published: 06 September 2016
Citation: 
Xiao X, Sun J, Yang T, Fang X, 
Cheng J, Xiong YQ and Liu Y-H 
(2016) Pharmacokinetic/
Pharmacodynamic Profiles of 
Tiamulin in an Experimental 
Intratracheal Infection Model of 
Mycoplasma gallisepticum. 
Front. Vet. Sci. 3:75. 
doi: 10.3389/fvets.2016.00075
Pharmacokinetic/Pharmacodynamic 
Profiles of Tiamulin in an experimental 
intratracheal infection Model of 
Mycoplasma gallisepticum
Xia Xiao1,2†, Jian Sun1†, Tao Yang1, Xi Fang1, Jie Cheng1, Yan Q. Xiong3,4 and Ya-Hong Liu1,2*
1 National Reference Laboratory of Veterinary Drug Residues (SCAU), College of Veterinary Medicine, South China 
Agricultural University, Guangzhou, China, 2 Jiangsu Co-Innovation Centre for Prevention and Control of Important Animal 
Infectious Diseases and Zoonoses, Yangzhou, Jiangsu, China, 3 Los Angeles Biomedical Research Institute, Harbor-UCLA 
Medical Center, Torrance, CA, USA, 4 David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
Mycoplasma gallisepticum is the most important pathogen in poultry among four patho-
genic Mycoplasma species. Tiamulin is a pleuromutilin antibiotic that shows a great 
activity against M. gallisepticum and has been approved for use in veterinary medicine 
particularly for poultry. However, the pharmacokinetic/pharmacodynamics (PK/PD) pro-
files of tiamulin against M. gallisepticum are not well understood. Therefore, in the current 
studies, we investigated the in vivo PK/PD profiles of tiamulin using a well-established 
experimental intratracheal infection model of M. gallisepticum. The efficacy of tiamulin 
against M. gallisepticum was studied in 8-day-old chickens after intramuscular (i.m.) 
administration at 10 doses between 0–80 mg/kg. Liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) was used to evaluate the PK parameters of tiamulin following 
i.m. administration at doses of 5, 40, and 80 mg/kg in Mycoplasma gallisepticum-infected 
neutropenic chickens. Real-time PCR (RT-PCR) was used for quantitative detection of 
M. gallisepticum. The MIC of tiamulin against M. gallisepticum strain S6 was 0.03 μg/mL. 
The PK/PD index, AUC24h/MIC, correlated well with the in vivo antibacterial efficacy. The 
in vivo data suggest that animal dosage regimens should supply AUC24h/MIC of tiamulin 
of 382.68 h for 2 log10 ccu equivalents M. gallisepticum reduction. To attain that goal, 
the administered dose is expected to be 45 mg/kg b.w. for treatment of M. gallisepticum 
infection with an MIC90 of 0.03 μg/mL.
Keywords: tiamulin, M. gallisepticum, in vivo PK/PD, chicken
inTrODUcTiOn
Mycoplasma gallisepticum (M. gallisepticum), a multi-host pathogen, is the most pathogenic agent 
of chronic respiratory disease (CRD) in poultry and turkey (1, 2). It can also be transmitted from 
poultry to house finches as well as other similar species and cause outbreaks of upper respiratory 
disease (3). Because it produces vast losses in the poultry industry, M. gallisepticum is considered as 
the most economically important pathogen of the four pathogenic Mycoplasma species (4).
Current means of controlling M. gallisepticum infections among avian species include biosurveil-
lance practices, vaccines, and medication (5). Despite control measures, M. gallisepticum may be 
present in chick flocks that are maintained for long growing periods with minimal biosecurity. Some 
live attenuated M. gallisepticum vaccines are approved for use only within the commercial egg layer 
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industry (6). The effectiveness of other subunit vaccines may be 
limited due to efficacy and associated costs (7). Although some 
vaccines are effective, M. gallisepticum outbreaks within vacci-
nated flocks has been observed (7), suggesting better medication 
control are required.
Antibiotics have been extensively used in the areas with 
intensive and varied population of poultry flocks for controlling 
M. gallisepticum or other pathogen infections (8). The use of 
antimicrobial agents has been considered as an economic method 
for controlling M. gallisepticum infections (8). Several kinds of 
antibiotics (macrolides, tetracyclines, fluoroquinolones, and 
pleuromutilin) have displayed good activity against M. gallisepti-
cum (9, 10). However, it has also been noticed that antibacterial 
usage over time can induce resistance in this organism (11, 12).
Tiamulin is a semisynthetic derivative of the diterpene antibi-
otic pleuromutilin used in swine and poultry for treatment and 
prophylaxis of dysentery, pneumonia, and mycoplasmal infec-
tions (13). Although it has been used over 30 years, no significant 
changes of susceptibility on this pathogen were observed previ-
ously (11, 14). However, one recent investigation indicated that 
tiamulin resistant isolates were seen after tiamulin treatment (15). 
Therefore, it is important to study the optimal tiamulin regimen 
in order to maximize antibacterial activity and to prevent emer-
gence of resistance. It is well-known that pharmacokinetic (PK) 
and pharmacodynamics (PDs) profiles of antibiotics provide 
useful information in the establishment of optimal dose regimens 
for better clinical setting management and prohibit resistance 
emergence (16, 17). To our best knowledge, PK/PD profiles of 
tiamulin against M. gallisepticum are very limited. Therefore, in 
the current experiment, we performed in  vivo PK/PD studies 
of tiamulin against M. gallisepticum after intramuscular (i.m.) 
administration. Though the i.m. administration has not been 
approved for tiamulin in chicks, this study would provide founda-
tion for tiamulin injectable formulation for chicks in future. The 
goals of the present investigations were to: (1) evaluate the PK 
profiles and dose proportionality of tiamulin in an intratracheal 
infection animal model; (2) provide the magnitude of the PK/PD 
index AUC24h/MIC for different extent of efficacies; and (3) estab-
lish a rational dosage regimen that optimizes tiamulin efficacy 
with respect to bacteriological and clinical outcomes.
MaTerials anD MeThODs
Bacteria, chemicals, susceptibility assay, 
and animals
A well-characterized M. gallisepticum standard virulent strain 
S6 was purchased from the Chinese Veterinary Microorganism 
Culture Collection Center (Beijing, China). Tiamulin 
Fumarate (>99%) was kindly supplied by the Hebei Yuanzheng 
Pharmaceutical Company (Hebei, China). The MIC of tiamulin 
on the strain S6 was determined by a standard micro-dilution 
method according to recommended protocols (18, 19). Three 
hundred fifty Sanhuang chickens of 1-day-old weighting 35~45 g 
supplied by Guangdong Academy of Agricultural Sciences 
(Guangzhou, Guangdong, China) were used in this experiment. 
Birds were free of M. gallisepticum and fed with clean water and 
antibacterial-free fodder.
In Vitro standard Dna Preparing
An in vitro DNA standard curve was established according to 
our previous report (19). Briefly, 36  h incubated M. gallisep-
ticum medium was centrifuged for 10  min at 1,500  rpm and 
then resuspending the pellet in 0.6  mL fresh M. gallisepticum 
medium. 0.1  mL of the sample was serial diluted for bacteria 
counting by culture method [color change unit per millimeter 
(ccu/mL)]. Meanwhile, DNA was isolated from the sample and 
serial 10-fold dilutions (100–10−6) prepared from the 0.6  mL 
sample with a bacteria DNA kit (Omega Bio-tek, Inc., Norcross, 
GA, USA). The DNA copies of M. gallisepticum were determined 
by real-time PCR (RT-PCR) (20). The DNA standard curve was 
plotted by the number of M. gallisepticum calculated from the 
culture method and cycle threshold (Ct) values obtained using 
RT-PCR results.
neutropenia Model
Two days post arrival, the chicken neutropenia model published 
by our laboratory (19) was established in this study in order to 
eliminate the immunity variance of different chickens and study 
the efficacy of tiamulin solely, via intramuscular administration 
of cyclophosphamide at 60  mg/kg for 3  days (21). Birds were 
severely granulocytopenic (absolute leukocyte count <1,000/mm3) 
and remained so for 8 days after the third injection of cyclophos-
phamide. The South China Agriculture University Animal ethics 
committee approved all in  vivo experiments with an approved 
number of 2014-08. In addition, all husbandry practices and 
experimental operations were performed with full consideration 
of animal welfare.
M. gallisepticum intratracheal 
infection Model
M. gallisepticum mainly invades the respiratory system in chick-
ens. Thus, an M. gallisepticum intratracheal infection model 
was utilized in this study according to Xia’s report (19). Briefly, 
24 h post the last dose of cyclophosphamide, 0.2 mL of solution 
containing approximately 108 color change unit (ccu) of the 
M. gallisepticum strain was inoculated intratracheally to neu-
tropenic chickens for 3 days [95% infective dose (ID95) for the 
studied strain]. Initial pathogen loading was quantified accord-
ing to our established method described in our previous report 
(19). Briefly, at 24 h after the last infection dose, chickens were 
euthanized and trachea, air sac, and lungs were collected, homog-
enized in 2 mL PBS and centrifuged at 500 rpm for 5 min. An 
aliquot of 0.5 mL supernatant was used for DNA extraction with 
a bacterial DNA kit (Omega Bio-tek, Inc., Norcross, GA, USA) as 
described above. DNA copies of M. gallisepticum in these samples 
were measured by RT-PCR as described above. The amount of M. 
gallisepticum was calculated using the DNA copies via the in vitro 
standard curve.
Determination of Dna copies of 
M. gallisepticum Using rT-Pcr
The method determinating DNA copies of M. gallisepticum in 
different samples by RT-PCR were identical with our previ-
ous report (19). All RT-PCR reactions were performed on a 
FigUre 1 | In vitro Dna standard curve. Relationship of DNA standards 
between Ct value and culture results (Log10 ccu/mL). Mean of three different 
RT-PCR runs.
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BIO-RAD iQ 5 (Bio-Rad Laboratories, Inc., USA) using the 
SYBR premix Ex Taq™ (TaKaRa, Shiga, Japan). Ct values were 
defined as the cycle number yielding a maximum value of the 
second derivative of the amplification curve of the sample. 
Samples were defined as positive when both a measurable 
Ct and the expected Tm (±0.5°C) were seen. The standard 
samples and a negative control (elution buffer) were included 
in each run.
Tiamulin Pharmacokinetics in neutropenic 
intratracheal infection Model
The infected neutropenic chickens were administrated with 
tiamulin intramuscularly at single doses of 5, 40, or 80  mg/kg 
b.w. 1.5  mL blood was sampled from the neck vein at 5, 10, 
30 min, 1, 2, 4, 6, 8, 12, and 24 h after drug administration (10 
chickens/time point). Blood samples were incubated immediately 
at room temperature for 1 h and then placed in 4°C for 2 h to 
enable clot retraction. Serum was obtained by centrifuging at 
3,000  rpm for 10  min and frozen at −20°C immediately until 
analysis within 2  weeks. Tiamulin was extracted from serum 
by acetonitrile with a proportion of 2:1. Concentrations of 
tiamulin in serum were determined via a high-performance 
liquid chromatography-tandem mass spectrometry (LC-MS/
MS) method, which was developed by our group and reported 
previously (22, 23). The recovery and precision were calculated 
by analysis of spiked samples at three concentration levels (5 
replicates of each concentration). Mean recoveries of tiamulin 
that spiked at three concentration levels were in the range of 
86.0–92.7%. The limit of quantitation (24) was confirmed at 
2.5  ng/mL. The coefficient of correlation (r2) was 0.9995 for 
the linear range of 2.5–500 ng/mL. The intra-day and inter-day 
coefficients of variation were determined to be 5.6 and 10.7%.
efficacy of Tiamulin in neutropenic 
chicken intratracheal infection Model
To evaluate the efficacy of tiamulin at 24 h post-three day infec-
tions, either 0.85% NaCl (controls) or tiamulin at 5, 10, 20, 
30, 40, 50, 60, 70, or 80  mg/kg were administrated to infected 
neutropenic chickens intramuscularly once daily for 3 days (five 
chickens/dose). At 24  h after the last drug administration, the 
amounts of M. gallisepticum in each chicken were calculated 
using the method described above.
Pharmacokinetics and 
Pharmacodynamics analysis
The PK profiles of tiamulin were analyzed by the non-compart-
mental model with uniform weighting using the WinNonlin 
software (version 6.1; Pharsight, CA, USA). The surrogate 
marker of antibacterial activity, AUC24h/MIC were calculated 
using in vitro MIC value and PK parameters obtained from three 
doses of i.m. administrations of tiamulin. The bacteria loading for 
each animal was calculated according to Ct values and the in vitro 
standard DNA curve. The efficacy of tiamulin was evaluated by 
the reduction of M. gallisepticum compared to the initial bacteria 
count before drug treatment. The in vivo PK/PD relationship of 
tiamulin against M. gallisepticum was studied using the sigmoid 
Emax model WINNONLIN software (version 6.1; Pharsight, CA, 
USA) with the equation as follows:
 
E E E C
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×
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where E0 is the change in log10 ccu equivalents/mL in the control 
sample (absence of tiamulin), Emax is the difference in log10 ccu 
equivalents/mL of the greatest amount of kill, Ce is the AUC24h/
MIC in the effect compartment, EC50 is the AUC24h/MIC value 
producing a 50% reduction in bacterial counts, and N is the Hill 
coefficient that describes the steepness of the curve (25).
Dosage calculation
In order to deduce a more rational regimen, the general formula 
was employed to estimate dosages for different magnitudes of 
efficiency (26).
 
Dose
CL AUC MIC MICperhour=
× ×
×
( / )24 90
F fu  
where dose is the optimal dose (milligram/kilogram/day), CL 
is the body clearance (liter/kilogram/day), AUC/MIC is the 
breakpoint marker for the desired effect (hour), MIC90 is the MIC 
inhibiting 90% of strains (milligram/liter), F is the bioavailability, 
and fu is the free drug fraction.
resUlTs
susceptibility Testing
The MIC of tiamulin against the studied strain was 0.03 μg/mL.
In Vitro standard Dna curve
The correlation between the Ct values and log10 ccu/mL reached 
statistic significance with the equation of y = −0.3087x + 10.44 
and R2 of 0.9988 (Figure  1). The limitation of detection was 
3 × 102 equivalents ccu/mL. The recovery rates at different dilu-
tions were 56.5 ± 5.1%.
TaBle 1 | Pharmacokinetic parameters of tiamulin in serum following 
intramuscular administration at a single dose of 5, 40, or 80 mg/kg in 
M. gallisepticum-infected chickens (n = 10/group).
Parameters (units) 5 mg/kg 40 mg/kg 80 mg/kg
Cmax(μg/mL) 2.05 8.8 14
Tmax(h) 0.167 0.167 0.167
T1/2β (h) 1.15 1.39 1.17
AUC24h (μg h/mL) 1.07 8.61 18.21
CL/F (L/h/kg) 4.53 4.6 4.37
MRTlast (h) 8.15 3.46 2.33
Cmax, maximum serum concentration; Tmax, time of maximum serum concentration; T1/2β, 
elimination half-life; AUC24h, 24 h area under serum concentration-time curve; CL/F, 
clearance divided by bioavailability; MRTlast, residence time.
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M. gallisepticum intratracheal 
infection Model
Major clinical symptoms, including depression, mouth breath-
ing, eye closures, were observed from the infected animals. In 
addition, histopathology studies showed that airsacculitis as the 
cardinal symptom of M. gallisepticum infection was observed 
in 95% infected chickens. The mean M. gallisepticum load was 
2.2 ×  106  ccu equivalents/mL for all inoculated chickens. The 
morbidity and mortality rates were 95 and 17% at 5 days post-
infection, respectively. Neither clinical symptoms nor airsacculitis 
were observed in the control animals. Bacteriological assays were 
also negative in the control group.
Tiamulin Pharmacokinetics Profiles in 
neutropenic intratracheal infection Model
The main PK parameters are presented in Table 1 and Figure 2. 
The Cmax were 2.05, 8.8, and 14 μg/mL for 5, 40, and 80 mg/kg 
doses, respectively, which were observed at 0.167 h after adminis-
tration. The half-life (T1/2β) was about 1.24 h for all three different 
doses. A second peak was observed for all the doses administered 
at 8–12  h. Importantly, a significant correlation between doses 
and AUC24h was observed (R2 = 0.999, Figure 3). As the AUC24h 
were increasing in a dose-dependent manner from 5 to 80 mg/kg, 
the AUC24h of other dose regimens were calculated according to 
the linear relationship. The parameters of CL were parameterized 
as CL/F because of the extravascular administration while MRTlast 
was the ratio of AUMClast/AUClast.
In Vivo efficacy of Tiamulin in neutropenic 
chicken intratracheal infection Model
The Ct values of respiratory tissues of chickens administrated 
with doses from 5 to 80 mg/kg increased with the increasing of 
doses, implying that the bacteria loading decreased with the dose 
increasing. The Ct value increased sharply between dosages of 10 
and 50 mg/kg while gently from 50 to 80 mg/kg (Figure 4). Limbs 
Twitch was observed in chickens treated with doses of 60, 70, 
80 mg/kg for about 10 min; however, no death emerged.
Tiamulin PK/PD Profiles
The PK/PD indices AUC24h/MIC was integrated using the PK 
parameters, dose proportionality, and MIC data. The effect (E) 
was calculated as the reduction of M. gallisepticum using the 
unit of Log10 ccu equivalent/mL. The relationship between the 
ratio of AUC24h/MIC and antibiotic efficacy was described using 
the Sigmoid Emax model (Figure 5). The AUC24h/MIC corrected 
well with the effects (R2 =  0.8979). The values of AUC24h/MIC 
for mycoplasmastasis (0 log10 ccu/mL reduction), for 1 log10 ccu 
reduction and 2 log10 ccu reduction are 98.98, 206.56, 382.58, 
respectively (Table 2). The EC50 was 211.19 h, and the slope of 
the graph (N) was 3.68.
Dosage calculation
To calculate dosages, the bioavailability was taken into account 
owing to the extravascular route of administration, and the free 
drug fraction was not required for using PD data generated 
in vivo. In order to provide a dosage regimen attaining maximum 
effect for chickens infected with M. gallisepticum with an MIC90 
of 0.03 μg/mL, a dose of 45 mg/kg for 3 days was recommended.
DiscUssiOn
M. gallisepticum, a highly transmissible, persistent pathogen 
in chickens, turkeys, and some wild birds, causes considerable 
economical losses to the poultry industry all over the world 
(27). Burch and Valks (28) had clarified that tiamulin pos-
sessed excellent activity against 241 M. gallisepticum strains 
by comparing the MIC of tiamulin against M. gallisepticum 
and the Cmax or concentration at steady state (Css) in chicken 
blood in 2002 (28). However, its chemotherapeutic properties 
are not well described. In addition, the use of PK/PD model to 
identify the PD activity by integrating the PK characters, MIC, 
and pathogen loading outcome has proven helpful in design-
ing rational dosage regimens in humans and animals (29, 30). 
Burch and Alvarez (31) evaluated the relationship between 
Cmax/MIC or AUC/MIC and prevention or treatment results of 
tiamulin in M. gallisepticum infection in 3-week-old chickens 
(31). The PK/PD parameters in his study were with some rough 
as he used the reported PKs of tiamulin in 7-week-old health 
chickens to predict that in 3-week-old M. gallisepticum-infected 
chickens. And the PDs of that study was evaluated by scores of 
lesions, and whether M. gallisepticum was isolated or not from 
air sacs. It is known that isolation of M. gallisepticum is easy to 
influence by overgrowth of faster growing Mycoplasma species 
or impeded by other organisms or no growth in subculture, so 
it may not be a good method to judge the PDs. What’s more, 
the study did not calculate the PDs from the aspect of bacteria 
loading reduction, which is important in PK/PD study. Thus, in 
this study, in vivo PK/PD profiles of tiamulin were established 
using PK characters in infected chickens, MIC, and pathogen-
loading outcome.
This was the first report about the PKs of tiamulin in 
M.   gallisepticum intratracheal-infected chicks. Tiamulin was 
rapidly absorbed with the peak concentrations for 5, 40, 80 mg/
kg dose of 2.05, 8.8, 14.0 μg/mL achieved at 0.167 h. The half-life 
was in the range of 1.15–1.39 h, which was lower than the value 
reported in dogs (4.7 h) (32), which indicated that the elimina-
tion of tiamulin was of significant difference among species. The 
rate and extent of absorption was constant among the tested 
doses with the values of clearance divided by bioavailability 
FigUre 2 | serum concentrations of tiamulin following i.m. administration at a single dose of 5, 40, or 80 mg/kg in M. gallisepticum intratracheal 
infection model (n = 10/time point).
FigUre 3 | linear regression plots between administered dose and 
aUc24h values.
FigUre 4 | The calculated in vivo M. gallisepticum counts after 
tiamulin treatment. (n = 4–7/dose).
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(CL/F) of 4.53, 4.6, 4.37 L/h/kg, respectively. That is to say, tia-
mulin showed dose-dependent PKs when given as a single i.m. 
dose of 5, 45, or 80 mg/kg b.w. This was in accordance with the 
report that tiamulin showed dose proportionality in the range 
of 10–25 mg/kg b.w. in dogs (32). This phenomenon was also 
confirmed in our previously research with valnemulin, which 
is also a semisynthetic derivative of the diterpene antibiotic 
pleuromutilin (19). A second peak was observed for all the 
doses administration at 8–12 h. Tiamulin mainly accumulates 
and metabolizes via liver. It was speculated that, according to the 
chemical structure, a relatively high liposolubility of tiamulin 
6Xiao et al. PK/PD of Tiamulin in M. gallisepticum-Infected Chicken
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would result in enterohepatic recycling, which is possibly the 
main reason that the second peak was observed (33).
The parameters of tiamulin (AUC24h) that showed dose 
proportionality in the range of 5–80  mg/kg following i.m. 
administration allowed us to calculate the AUC24h for other 
dosage administrations. As reported for other pleuromutilin 
derivatives (34, 35), the PK/PD surrogate of pleuromutilin 
derivatives is AUC24h/MIC. The data from the present multiple 
dosage studies of tiamulin confirmed the conclusion that the 
AUC24h/MIC was the PK/PD index of tiamulin. The values of 
AUC24h/MIC for mycoplasmastasis (0 log10 ccu equivalents 
reduction), activity of 1 log10 ccu equivalents reduction, and 
2 log10 ccu equivalents reduction were 124, 205, and 327  h, 
respectively, which were much lower than those obtained from 
FigUre 5 | sigmoid Emax relationships of tiamulin between antimycoplasmal effect (E, log10 ccu equivalents/ml) and in vivo aUc24h/Mic ratio against 
Mg in serum of chickens.
an in vivo study of valnemulin (28,820, 38,030, and 56,256 h, 
respectively) (36). One possible reason for the differences was 
that the concentration in serum was not that real one act on 
M. gallisepticum as the infection site is air sac or respiratory 
system, and antibiotic concentrations in air sac or lung are 
usually different from those in serum (14). Another reason 
could be that the distribution volume of timulin was much 
wider than that of valnemulin in chickens, which means that 
the tissue concentration of tiamulin maybe higher than that of 
valnemulin (36). Tiamulin did not reach a mycoplasmacidal 
effect (3 log10 ccu equivalents reduction), which was in accord-
ance with Burch and Alvarez’s (31) results that even tiamulin 
concentration far exceeded the MBC could not eliminate the 
pathogen in treatment procedure (31).
As was observed in this investigation, doses over 60  mg/kg 
would trigger neuro-toxicity. The calculated dose of 45  mg/kg 
for 3 days was sufficient for clinical treatment of M. gallisepticum 
infection with an MIC90 of 0.03 μg/mL. This regimen was in the 
range of recommended doses for drinking water (30–60 mg/kg) 
in poultry but more than twice of the recommended dose range 
for i.m. administration (10–20 mg/kg) in pigs (13). It was also 
lower than the neuro-toxicity dose. Though the i.m. administra-
tion has not been approved for tiamulin in chicks, this result 
would provide foundation for tiamulin injectable formulation 
for chicks in future.
The conventional method for evaluating the efficacy of an 
antibacterial agent is bacteria counting by culture method. 
However, the cultivation technique is expensive and laborious 
and time consuming (37). Also, this gold standard for M.  gal-
lisepticum was  usually influenced by overgrowth of faster 
TaBle 2 | Tiamulin PK/PD analysis with the parameter of aUc24h/Mic in 
M. gallisepticum intratracheal infection model.
Parameter Value sD
Emax (Log10 ccu equivalents/mL) 2.38 0.24
E0 (Log10 ccu equivalents/mL) 0.14 0.13
EC50 (h) 211.19 20.3
AUC24h/MIC for 0 log10 ccu equivalents/mL reduction (h) 98.98
AUC24h/MIC for 1 log10 ccu equivalents/mL reduction (h) 206.56
AUC24h/MIC for 2 log10 ccu equivalents/mL reduction (h) 382.58
Slope (N) 3.68 1.2
E0 is the change in Log10 ccu equivalents/mL after 24 h incubation in the control 
sample (absence of drug) compared with the initial inoculum. Emax is the difference in 
effect of the greatest amount of kill. EC50 is the AUC24h/MIC value producing a 50% 
reduction in bacterial counts from the initial inoculum. AUC24h/MIC is the 24 h area 
under concentration-time curve/minimum inhibitory concentration ratios. N is the Hill 
coefficient that describes the steepness of the AUC24h/MIC-effect curve.
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